



The 4th Annual Proton Therapy Training Course to be held at Penn Medicine's Department of Radiation Oncology

Inspiring Innovation to transform Patient Care

Louvain-La-Neuve, Belgium, Philadelphia, Pennsylvania USA, 24th August 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer and the department of Radiation Oncology at Penn Medicine (Philadelphia, PA) in partnership with OncoLink, proudly presents the Fourth Annual Course on Proton Therapy: Inspiring Innovation to transform Patient Care, that will be held on November 17-19, 2017 in Philadelphia, PA.

This unique educational opportunity presents medical professionals and administrators interested in proton therapy with a three-day proton therapy immersion program at Penn Medicine. The fourth presentation of this course will focus on *Inspiring Innovation to Transform Patient Care*.

The course offers in-depth insights to the practical application of proton therapy for administrators, clinicians and medical physicists from cancer centers considering establishing proton therapy.

Andrew Dike, Proteus[®]SERVICES Product Manager at IBA, explains "proton therapy has changed the landscape of radiation therapy and is a powerful weapon in the fight against cancer. Today, less than 1% of patients are treated with protons. This course provides an interactive forum to better understand what it takes to make proton therapy a reality in a health system or cancer center. IBA is proud to be part of such an important event that helps the field of proton therapy grow to eventually reach 20% or more of patients who could benefit from this treatment option.

Over the past two years, the course has received very positive feedback from attendees stating that the material presented is practical and useful in daily operations.

James Metz, MD, Chair, Penn Radiation Oncology and Executive Director, OncoLink said:

"We are excited to offer this course for the fourth year. As the interest in proton therapy grows both nationally and internationally, Penn's Roberts Proton Therapy Center continues to be a leader in providing education and training to help develop the next wave of experts in the field. We have been pioneers, both in regards to the technology and in building staff expertise, and we are pleased to showcase our Center and share our experience with the world."

Anders Navrsted Pedersen, clinical director of the radiotherapy program at Copenhagen University Hospital (Rigshospitalet) in Denmark commented: "I attended the course in order to advise patients, refer patients, prepare comparison dose plans and prepare for proton therapy in my own center".

Sanford Katz, MD, radiation oncologist at the Willis-Knighton Cancer Center in Shreveport, LA: "I returned from the seminar with interesting new views which we now consider for our treatment planning and program. All the speakers were approachable and encouraged us to contact them in case of questions, which really gave the feeling that if you were to embark on this big journey, you become part of and are backed up by a community of like-minded peers."



Target audiences for the course are: radiation oncology physicians, physicists, and administrators who are interested in learning about proton therapy. At the end of this educational activity, participants should be able to:

- Understand the logistics of establishing a proton therapy center with clinical and research capabilities
- Describe the current clinical indications and applications for proton therapy
- Comprehend the various technical considerations in proton therapy planning
- Explain the regulatory aspects of proton therapy planning and delivery from the standpoints of quality assurance and compliance
- Better perform their specific roles within the proton therapy center

Details:

When: Friday, November 17, 2017 - Sunday, November 19, 2017

Where: Philadelphia, PA, USA

For more information on registration and other course details, please visit our website at <https://protontherapycourse.cvent.com>

Contact us at courses@protontherapyeducation.com with any questions.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing around 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the Pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com



About OncoLink

OncoLink was the first online cancer information site, started in 1994, and remains one of the largest. This award-winning site is maintained by a group of oncology healthcare professionals who understand the need of patients, caregivers and healthcare professionals. OncoLink's content is continually updated and ranges from treatment and disease information for a newly diagnosed patient, support through the side effects of treatment, and into survivorship. OncoLink provides tools and educational materials to support the practice of busy practitioners.

The primary goal of OncoLink is to support patients, caregivers and practitioners through education. This education can empower patients to make informed treatment decisions, be active participants in their care and be their own advocate. More information can be found at:
<https://www.oncolink.org/>

The Roberts Proton Therapy Center at the University of Pennsylvania is the largest, most advanced facility of its kind in the world, and the only proton therapy center that is fully integrated with a National Cancer Institute. (NCI) designated comprehensive cancer center.

For further information, please contact:

IBA

Thomas Ralet

Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

Andrew Dike

+32 10 203 735
andrew.dike@IBA-group.com